7.36
-0.18(-2.39%)
Currency In USD
| Previous Close | 7.54 |
| Open | 7.59 |
| Day High | 7.8 |
| Day Low | 7.36 |
| 52-Week High | 34.11 |
| 52-Week Low | 5.9 |
| Volume | 1.26M |
| Average Volume | 2.59M |
| Market Cap | 537.22M |
| PE | -11.15 |
| EPS | -0.66 |
| Moving Average 50 Days | 7.47 |
| Moving Average 200 Days | 16.5 |
| Change | -0.18 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $458.57 as of July 01, 2025 at a share price of $7.36. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $215.52 as of July 01, 2025 at a share price of $7.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
GlobeNewswire Inc.
Jun 13, 2025 11:00 AM GMT
– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In combination with small molecule inhibitors, ARV-393
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
GlobeNewswire Inc.
Jun 06, 2025 11:00 AM GMT
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITA
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
GlobeNewswire Inc.
Jun 05, 2025 12:28 PM GMT
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in com